Novo Nordisk rebrands to ‘Novo’ under CEO Mike Doustdar
People walk past a sign for Novo Nordisk’s annual general meeting at the entrance to the venue in…
This medical device stock looks like a gift for patient investors
Insulet is a high-quality compounder where a temporary execution issue is masking strong underlying fundamentals. Type 2 diabetes…
Novo Nordisk CEO defends lawsuit against Eli Lilly: ‘Competition has to be fair’
Novo Nordisk CEO Mike Doustdar on Wednesday defended the drugmaker’s decision to sue rival Eli Lilly over its…
Eli Lilly’s weight loss pill Foundayo gets UK approval. Plus, oil holds back stocks
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…
Foundayo: Eli Lilly wins U.K. approval, challenging Wegovy weight-loss pill
Eli Lilly has won its first approval to sell its weight-loss drug Foundayo outside the U.S., allowing it…
Eli Lilly, Novo Nordisk earnings show widening divide in GLP-1 market
The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters The diverging paths of…
We’re increasing our Eli Lilly price target after another beat-and-raise quarter
Eli Lilly on Wednesday reported better-than-expected quarterly results and raised its full-year guidance as the company’s portfolio of…
Eli Lilly (LLY) earnings Q2 2026
Eli Lilly on Wednesday reported second-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook,…
Novo Nordisk releases earnings and guidance
Novo Nordisk CEO Maziar Mike Doustdar waits for the start of the pharmaceutical company’s annual general meeting in…
Novo Nordisk shares fall after heart medicine trial results
Shares of Novo Nordisk fell as much as 10% on Friday after the drugmaker said a late-stage heart…
Novo Nordisk sued by shareholders over weight-loss drug: What to know
Novo Nordisk shareholders are suing the drugmaker over its experimental obesity treatment CagriSema, alleging the company misled investors…
Novo Nordisk looks to block Eli Lilly weight-loss drug ads
The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters Novo Nordisk said on…